NCT07870265Recruiting
Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
The goal of this prospective, low-interventional study is to develop and optimize a highly sensitive and specific method for the detection of the BRAF V600E mutation in liquid biopsy samples from patients with unresectable metastatic melanoma after disease relapse. The method will be based on a CRISPR/Cas12a system combined with isothermal amplification and endpoint electrochemical detection using electrode chips and low-cost instrumentation.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 17 (estimated)
- First submitted
- 6 Oct 2026
- Start date
- 20 Oct 2026
- Primary completion date
- 20 Oct 2027
- Lead sponsor
- Masaryk Memorial Cancer Institute
- Diseases
- Melanoma
- NCT number
- NCT07870265
What you commit to
- Study type: Interventional
- Planned participants: 17
- From 20 Oct 2026 to the primary completion date, 20 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving palliative care with an estimated life expectancy ≤ 3 months.
- Severe alcohol and/or drug abuse during therapy.
Other illness
- Operable disease relapse.
Age
- Age under 18 years.
Other
- Pregnant or breastfeeding women.
- Inability to obtain a valid biological sample for molecular analysis
Who the study is looking for
- Age ≥ 18 years.
- Subject willing and able to provide written informed consent for biological sample collection.
- Ability to communicate effectively with the investigator in the local language, as well as the ability to understand and comply with study requirements.
- Histologically confirmed malignant melanoma.
- Radiologically or histologically confirmed disease relapse.
- Feasibility/possibility of peripheral blood sampling for ctDNA analysis.
- Documented, known \*BRAF\* mutation status (wild-type vs. V600E).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Masaryk Memorial Cancer Institute Coordinator of this site? Confirm its status | Brno | Czechia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.